Your browser is no longer supported. Please, upgrade your browser.
MGTA Magenta Therapeutics, Inc. daily Stock Chart
Magenta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own16.23% Shs Outstand39.61M Perf Week-3.56%
Market Cap341.08M Forward P/E- EPS next Y-2.01 Insider Trans18.94% Shs Float29.10M Perf Month3.98%
Income-83.30M PEG- EPS next Q-0.45 Inst Own73.60% Short Float5.51% Perf Quarter-5.62%
Sales- P/S- EPS this Y33.80% Inst Trans0.11% Short Ratio7.74 Perf Half Y-23.87%
Book/sh4.39 P/B1.61 EPS next Y-5.20% ROA-49.50% Target Price- Perf Year-25.00%
Cash/sh3.65 P/C1.93 EPS next 5Y- ROE-55.40% 52W Range5.76 - 16.19 Perf YTD-53.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.45% Beta-
Dividend %- Quick Ratio17.30 Sales past 5Y- Gross Margin- 52W Low22.40% ATR0.42
Employees72 Current Ratio17.30 Sales Q/Q- Oper. Margin- RSI (14)47.94 Volatility5.75% 5.29%
OptionableYes Debt/Eq0.00 EPS Q/Q0.30% Profit Margin- Rel Volume3.04 Prev Close7.07
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume207.15K Price7.05
Recom1.70 SMA20-1.43% SMA50-1.81% SMA200-21.14% Volume629,963 Change-0.28%
Jun-08-20Upgrade Goldman Neutral → Buy $15
Mar-25-19Downgrade Goldman Buy → Neutral $17 → $16
Mar-15-19Initiated Raymond James Outperform
Jul-16-18Initiated Wedbush Outperform $22
Jul-16-18Initiated JP Morgan Overweight $18
Jul-16-18Initiated Goldman Buy $18
Oct-07-20 12:46PM  
Sep-29-20 10:48AM  
Sep-11-20 08:00AM  
Sep-02-20 12:00PM  
Aug-31-20 08:00AM  
Aug-13-20 03:30PM  
Aug-06-20 08:00AM  
Aug-04-20 08:28AM  
Aug-03-20 04:05PM  
Jul-15-20 07:58PM  
Jul-08-20 03:44PM  
Jul-06-20 05:10PM  
Jul-05-20 07:00AM  
Jun-30-20 08:00AM  
Jun-24-20 08:20PM  
Jun-22-20 06:54PM  
Jun-20-20 07:10PM  
Jun-17-20 12:40PM  
Jun-16-20 03:03PM  
Jun-15-20 11:00AM  
Jun-13-20 09:09AM  
Jun-12-20 10:45AM  
Jun-11-20 03:09PM  
Jun-08-20 04:30PM  
Jun-05-20 08:30AM  
May-14-20 08:00AM  
May-07-20 07:30AM  
May-06-20 07:00AM  
Apr-30-20 08:00AM  
Apr-28-20 04:30PM  
Apr-17-20 08:11AM  
Apr-16-20 08:00AM  
Apr-07-20 01:21PM  
Mar-03-20 08:00AM  
Feb-26-20 08:30AM  
Feb-24-20 08:30AM  
Feb-20-20 08:30AM  
Feb-16-20 08:25AM  
Feb-06-20 08:30AM  
Feb-05-20 08:30AM  
Jan-13-20 08:00AM  
Jan-06-20 08:30AM  
Dec-19-19 09:54PM  
Dec-11-19 09:47AM  
Dec-09-19 07:45AM  
Dec-07-19 05:30PM  
Dec-01-19 09:30AM  
Nov-26-19 04:05PM  
Nov-13-19 08:00AM  
Nov-11-19 08:30AM  
Nov-06-19 09:00AM  
Oct-30-19 09:31AM  
Oct-16-19 08:30AM  
Oct-09-19 08:14AM  
Oct-08-19 09:56AM  
Sep-04-19 08:30AM  
Aug-08-19 08:00AM  
Aug-06-19 08:30AM  
Jul-12-19 02:29PM  
Jun-24-19 04:05PM  
Jun-22-19 07:57AM  
Jun-06-19 04:05PM  
May-09-19 08:00AM  
May-06-19 04:05PM  
May-01-19 08:11PM  
Apr-29-19 04:32PM  
Apr-24-19 08:30AM  
Apr-07-19 06:00PM  
Mar-20-19 12:07PM  
Mar-19-19 07:30AM  
Mar-15-19 01:32PM  
Mar-06-19 04:05PM  
Feb-25-19 08:15AM  
Feb-21-19 08:00AM  
Feb-07-19 08:30AM  
Jan-02-19 08:30AM  
Dec-02-18 09:00PM  
Dec-01-18 12:30PM  
Nov-26-18 08:30AM  
Nov-19-18 08:00AM  
Nov-08-18 08:00AM  
Nov-01-18 09:00AM  
Sep-24-18 08:30AM  
Aug-09-18 04:05PM  
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth BruceDirectorJun 29Buy8.001,250,00010,000,0001,250,000Jul 01 04:48 PM
GARDNER JASONSee RemarksJan 10Sale15.2511,200170,800251,212Jan 10 05:01 PM
DAVIS JOHN C. JRChief Medical OfficerJan 02Option Exercise9.4911,294107,18019,598Jan 03 04:01 PM
GARDNER JASONSee RemarksJan 02Sale15.102,80042,280262,412Jan 03 04:01 PM
DAVIS JOHN C. JRChief Medical OfficerJan 02Sale15.0411,294169,8178,304Jan 03 04:01 PM
ZDRAVESKI ZORANSee RemarksDec 24Sale16.007,902126,432128,009Dec 26 04:11 PM
ISACSON CHRISTINA K.Chief Business OfficerDec 24Sale16.014,46371,45383,786Dec 26 04:12 PM
ISACSON CHRISTINA K.Chief Business OfficerDec 23Sale16.039,867158,16888,249Dec 26 10:12 AM
ZDRAVESKI ZORANSee RemarksDec 23Sale16.034,18167,021135,911Dec 26 10:13 AM
GARDNER JASONSee RemarksDec 23Sale15.102,89743,755265,212Dec 23 04:41 PM
DAVIS JOHN C. JRChief Medical OfficerDec 20Option Exercise9.499198,7219,223Dec 20 05:52 PM
GARDNER JASONSee RemarksDec 20Sale15.1676,7111,162,617268,109Dec 20 06:22 PM
DAVIS JOHN C. JRChief Medical OfficerDec 20Sale15.0091913,7858,304Dec 20 05:52 PM
DAVIS JOHN C. JRChief Medical OfficerDec 10Option Exercise9.4917,055161,85225,359Dec 11 04:03 PM
DAVIS JOHN C. JRChief Medical OfficerDec 10Sale15.0017,055255,8258,304Dec 11 04:03 PM
GARDNER JASONSee RemarksDec 10Sale15.104,39266,319344,820Dec 13 05:08 PM
DAVIS JOHN C. JRChief Medical OfficerDec 09Option Exercise9.494,61443,78712,918Dec 11 04:03 PM
DAVIS JOHN C. JRChief Medical OfficerDec 09Sale15.004,61469,2108,304Dec 11 04:03 PM
COOKE MICHAEL P.Chief Scientific OfficerDec 02Sale13.007,50097,520240,523Dec 02 08:29 PM
COOKE MICHAEL P.Chief Scientific OfficerNov 20Sale12.005,00060,000248,023Nov 25 08:52 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.